SAN DIEGO, Feb. 24, 2011 /PRNewswire/ -- Gen-Probe
Incorporated (Nasdaq: GPRO) announced today that the Company will
present at three upcoming investor conferences:
- RBC Capital Markets' Healthcare Conference in New York at 10 a.m.
Eastern Time (ET) on March 2.
The Company also will participate in a panel discussion
entitled The Future of Molecular Testing at 3:35 p.m. ET the same day.
- Cowen and Company's 31st Annual Healthcare Conference in
Boston at 10:15 a.m. ET on March
9.
- Barclays Capital's 2011 Global Healthcare Conference in
Miami at 3:15 p.m. ET on March
16.
The presentations and the panel discussion will be webcast live
and may be accessed through a link on the investors section of
Gen-Probe's website at www.gen-probe.com. The webcasts will
be available for 30 days following the events.
About Gen-Probe
Gen-Probe is a global leader in the development, manufacture and
marketing of rapid, accurate and cost-effective molecular
diagnostic products and services that are used primarily to
diagnose human diseases, screen donated human blood, and ensure
transplant compatibility. Gen-Probe has approximately 28
years of expertise in nucleic acid testing (NAT), and received the
2004 National Medal of Technology, America's highest honor for
technological innovation, for developing NAT assays for blood
screening. Gen-Probe is headquartered in San Diego and employs approximately 1,400
people. For more information, go to www.gen-probe.com.
Caution Regarding Forward-Looking Statements
Any statements in this press release about our expectations,
beliefs, plans, objectives, assumptions or future events or
performance are not historical facts and are forward-looking
statements. Forward-looking statements are not guarantees of
performance. They involve known and unknown risks, uncertainties
and assumptions that may cause actual results to differ materially
from those expressed or implied. For information about risks
and uncertainties we face and a discussion of our financial
statements and footnotes, see documents we have filed with the SEC,
including our most recent Form 10-K, and all subsequent periodic
filings. We assume no obligation and expressly disclaim any
duty to update any forward-looking statement to reflect events or
circumstances after the date of this press release or to reflect
the occurrence of unanticipated events.
Contact:
|
|
|
|
Paula Izidoro
|
|
Investor Relations
|
|
858-410-8904
|
|
|
SOURCE Gen-Probe Incorporated